IP Library Patent Application 17416200
Patent Application
App. No. 17/416,200

MEDIA AND METHODS FOR DIFFERENTIATING NATURAL KILLER CELLS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/416,200
Abstract

Media and methods for differentiating NK progenitor cells into NK cells are disclosed. The NK differentiation media comprises a pyrimidoindole compound such as UM171 or UM729.

Claims (28)

1 . An NK cell differentiation medium, comprising a pyrimidoindole compound.

2 . The NK cell differentiation medium according to claim 1 , wherein the pyrimidoindole compound is UM171 or UM729.

3 . The NK cell differentiation medium according to claim 1 , further comprising a basal medium.

4 . The NK cell differentiation medium according to claim 3 , further comprising one or more of SCF, FLT3L, IL-2, IL-3, IL-15, or IL-7.

5 . The NK cell differentiation medium according to claim 1 , wherein the NK cell differentiation medium is not conditioned by contact with stromal cells or a stroma cell replacement.

6 . The NK cell differentiation medium according to claim 1 , wherein the NK cell differentiation medium does not include an aryl hydrocarbon receptor antagonist.

7 . The NK cell differentiation medium according to claim 1 , wherein the NK cell differentiation medium is serum-free.

8 . The NK cell differentiation medium according to claim 1 , wherein the NK cell differentiation medium differentiates NK cell progenitors.

9 . The NK cell differentiation medium according to claim 8 , wherein the NK cell progenitors are isolated or derived from a primary sample, or are derived from pluripotent stem cells.

10 - 11 . (canceled)

12 . A method for differentiating NK cells, comprising:

providing a population of NK cell progenitors; and

contacting the population of NK cell progenitors in culture with the medium of claim 1 at a concentration and for a time sufficient to yield NK cells,

wherein the NK cells express CD56.

13 . The method according to claim 12 , wherein the population of NK cell progenitors express CD7 or CD5, or both.

14 - 15 . (canceled)

16 . The method according to claim 12 , wherein the NK cells increase in frequency during the contacting step or increase in number during the contacting step, or both.

17 . (canceled)

18 . The method according to claim 12 , wherein the population of NK cell progenitors increase or decrease in frequency or number during the contacting step.

19 . The method according to claim 12 , wherein the providing and contacting steps are not in the presence of stromal cells or a stroma cell replacement.

20 . The method according to claim 12 , wherein the providing and contacting steps are not in the presence of an aryl hydrocarbon receptor antagonist.

21 . The method according to claim 12 , wherein the concentration of the pyrimidoindole compound is between 10 nM and 3 μM.

22 . The method according to claim 12 , wherein the time is at least 1 week or about 2 weeks.

23 - 24 . (canceled)

25 . The method according to claim 12 , wherein the NK cells are cytotoxic.

26 . The method according to claim 12 , wherein the population of NK cell progenitors is derived or isolated from a primary sample.

27 - 28 . (canceled)

29 . The method according to claim 12 , wherein the population of NK cells is differentiated from a pluripotent stem cell.

Assignments (2)
SECURITY INTEREST Recorded Jun 30, 2022
From: STEMCELL TECHNOLOGIES CANADA INC.
To: HSBC BANK CANADA
Reel/Frame 060544/0596 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 18, 2021
From: TABATABAEI-ZAVAREH, NOOSHIN; WOGNUM, ALBERTUS WERNERUS
To: STEMCELL TECHNOLOGIES CANADA INC.
Reel/Frame 056587/0283 →